The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 674.50
Bid: 677.50
Ask: 678.50
Change: -4.50 (-0.66%)
Spread: 1.00 (0.148%)
Open: 676.50
High: 686.00
Low: 674.50
Prev. Close: 679.00
TATE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FULL PENSION SCHEME BUY-IN WITH LEGAL & GENERAL

19 Sep 2019 07:00

RNS Number : 8661M
Tate & Lyle PLC
19 September 2019
 

 

 

TATE & LYLE ENTERS INTO FULL DEFINED BENEFIT PENSION SCHEMEBUY-IN WITH LEGAL & GENERAL

 

Agreement will deliver security for UK Scheme members while removing future riskfor Tate & Lyle and saving £20 million of annual contributions

 

19 September, 2019, London, UK: Tate & Lyle PLC ("the Company") and the Trustee of the Tate & Lyle Group Pension Scheme ("the Scheme"), the Group's UK pension scheme, today announce an agreement for a £930 million bulk annuity insurance 'buy-in' with Legal & General Assurance Society Limited ("Legal & General"). The agreement provides certainty and security for the Scheme's affected members.

 

The buy-in secures an insurance asset from Legal & General that fully1 matches the remaining pension liabilities of the Scheme, with the result that the Company no longer bears any investment, longevity, interest rate or inflation risk in respect of the Scheme. Under the transaction, the Company will not contribute any incremental funding into the Scheme1.

 

The agreement is not anticipated to impact profit before tax for the year ending 31 March 2020 but will eliminate non-cash net finance income on the UK scheme accounting surplus2 from the 2021 financial year. De-recognition of the accounting surplus will result in a decrease in Group net equity by around £180 million.

 

Imran Nawaz, Chief Financial Officer of Tate & Lyle PLC, said:

 

"This transaction represents a good outcome for our UK scheme members, the Company and our shareholders. We have supported the Scheme over many decades and made significant cash contributions to remedy a deficit that has existed between the Scheme's assets and liabilities. That funding, combined with excellent stewardship by the Scheme's trustees, has meant that the Scheme can now be de-risked for the benefit of members and the Company.

 

"Importantly, cash contributions into the Scheme will cease, saving around £20 million of cash annually from the 2021 financial year1, allowing the Company to focus our future investments on delivering profitable growth."

 

Michael Chatterton, Chairman of Trustees of the Scheme, said:

 

"This is great news for Scheme members. After many years of funding from Tate & Lyle and careful management, working together in close partnership with the Company, we have now secured our members' benefits through Legal & General. As a result, our members can continue to look forward to enjoying retirement knowing that their pensions are secure."

 

 

1 Subject to final price adjustment for bulk annuity pricing.

2 In the year ended 31 March 2019 net finance income on the UK scheme was £5 million.

 

END

 

Contacts:

 

Anna Taylor (media)

Corporate PR Manager

Tel: +44 (0)207 257 2209 or mobile: +44 (0)7766 361 515

mediaenquiries@tateandlyle.com

 

Christopher Marsh (investors)

VP Investor Relations

Tel: +44 (0) 20 7257 2110 or Mobile: +44 (0) 7796 192 688

 

 

About Tate & Lyle: 

 

Tate & Lyle is a global provider of solutions and ingredients for food, beverage and industrial markets.

 

Tate & Lyle operates through two global divisions, Food & Beverage Solutions and Primary Products, supported by the Innovation and Commercial Development and Global Operations teams. Food & Beverage Solutions is focused on growth by building leading positions globally in the categories of beverages, dairy, and soups, sauces and dressings. Primary Products is focused on delivering steady earnings and generating cash.

 

Food & Beverage Solutions consists of: Texturants, including speciality starches; Sweeteners, including low- and no-calorie sweeteners; and a Health and Wellness portfolio comprising mainly speciality fibres; and Stabilisers and Functional Systems, which are bespoke ingredient blends that ensure foods retain their structure.

 

Primary Products consists of high-volume sweeteners, industrial starches and fermentation products (primarily acidulants). It also sells co-products from the corn milling process as animal nutrition.

 

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2019, Tate & Lyle sales totalled £2.8 billion.

 

For more information, please visit http://www.tateandlyle.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCCKFDKABKDDCD
Date   Source Headline
8th May 20243:15 pmRNSHolding(s) in Company
1st May 20242:30 pmRNSTotal Voting Rights
25th Apr 20243:45 pmRNSHolding(s) in Company
24th Apr 20247:00 amRNSDirectorate Change
22nd Apr 20242:30 pmRNSDirector/PDMR Shareholding
19th Apr 202410:15 amRNSHolding(s) in Company
17th Apr 20244:15 pmRNSHolding(s) in Company
17th Apr 202410:30 amRNSHolding(s) in Company
15th Apr 202410:30 amRNSHolding(s) in Company
10th Apr 20243:45 pmRNSHolding(s) in Company
8th Apr 202411:15 amRNSHolding(s) in Company
5th Apr 20243:45 pmRNSHolding(s) in Company
4th Apr 20244:15 pmRNSHolding(s) in Company
4th Apr 202412:30 pmRNSHolding(s) in Company
4th Apr 202411:30 amRNSDirector/PDMR Shareholding
2nd Apr 202412:45 pmRNSTotal Voting Rights
2nd Apr 202411:30 amRNSHolding(s) in Company
28th Mar 202411:45 amRNSHolding(s) in Company
25th Mar 202411:45 amRNSHolding(s) in Company
21st Mar 20244:10 pmRNSHolding(s) in Company
20th Mar 20243:00 pmRNSHolding(s) in Company
20th Mar 202412:00 pmRNSHolding(s) in Company
19th Mar 20242:00 pmRNSHolding(s) in Company
13th Mar 20244:00 pmRNSHolding(s) in Company
12th Mar 20244:24 pmRNSHolding(s) in Company
12th Mar 20244:22 pmRNSHolding(s) in Company
7th Mar 20247:00 amRNSDirectorate Change
4th Mar 20242:00 pmRNSDirector/PDMR Shareholding
4th Mar 20241:45 pmRNSHolding(s) in Company
28th Feb 20242:30 pmRNSHolding(s) in Company
21st Feb 20247:00 amRNSTrading Statement
1st Feb 202412:00 pmRNSTotal Voting Rights
11th Jan 20241:00 pmRNSDirector/PDMR Shareholding
2nd Jan 202412:00 pmRNSBlock listing Interim Review
8th Dec 202311:45 amRNSDirector/PDMR Shareholding
6th Dec 202310:30 amRNSHolding(s) in Company
27th Nov 20234:15 pmRNSHolding(s) in Company
23rd Nov 20232:30 pmRNSHolding(s) in Company
20th Nov 202310:00 amRNSHolding(s) in Company
9th Nov 20237:00 amRNSHalf-year Report
8th Nov 20237:00 amRNSDirectorate Change
23rd Oct 202310:30 amRNSHolding(s) in Company
16th Oct 202310:30 amRNSHolding(s) in Company
13th Oct 202310:30 amRNSHolding(s) in Company
12th Oct 202311:00 amRNSHolding(s) in Company
2nd Oct 202310:23 amRNSDirector Declaration
1st Sep 202311:00 amRNSTotal Voting Rights
25th Aug 20233:45 pmRNSHolding(s) in Company
17th Aug 20234:30 pmRNSHolding(s) in Company
15th Aug 20234:30 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.